A SECRET WEAPON FOR SEMAGLUTIDE WEEK 1-6 BUNDLE

The trial accomplished equally its Most important endpoints, with semaglutide 2.4 mg demonstrating statistically considerable and exceptional improvements in liver fibrosis with no worsening of steatohepatitis, as well as resolution of steatohepatitis without worsening of liver fibrosis in individuals with MASH when compared with placebo.1Inactive